Menu
Search
|

Menu

Close
X

Knight Therapeutics Inc GUD.TO (Toronto Stock Exchange)

8.25 CAD
-- (--)
As of Nov 13
chart
Previous Close 8.25
Open --
Volume --
3m Avg Volume 97,258
Today’s High --
Today’s Low --
52 Week High 8.81
52 Week Low 7.38
Shares Outstanding (mil) 142.77
Market Capitalization (mil) 1,252.05
Forward P/E 59.75
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 10 analysts

KEY STATS

Revenue (mm, CAD)
FY18
9
FY17
9
FY16
6
FY15
1
EPS (CAD)
FY18
0.166
FY17
0.120
FY16
0.146
FY15
0.359
*Note: Units in Millions of Canadian Dollars
**Note: Units in Canadian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
59.75
33.64
Price to Sales (TTM)
vs sector
157.15
5.95
Price to Book (MRQ)
vs sector
1.28
4.89
Price to Cash Flow (TTM)
vs sector
59.49
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
2.19
14.22
Return on Equity (TTM)
vs sector
2.19
15.99

EXECUTIVE LEADERSHIP

James Gale
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Samira Sakhia
President, Chief Financial Officer, Director, Since 2017
Salary: $262,500.00
Bonus: --
Jonathan Goodman
Chief Executive Officer, Director, Since 2013
Salary: $300,000.00
Bonus: --
Amal Khouri
Vice President - Business Development, Since
Salary: $228,721.00
Bonus: --
Nancy Harrison
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

3400 De Maisonneuve West
MONTREAL   QC   H3Z 3B8

Phone: +1514.4844483

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

SPONSORED STORIES